• BetterLife appointed biopharmaceutical executive John W. LaRocca to its board in July 2026; he will also join the audit committee.
• LaRocca previously served as chief legal officer, corporate secretary, and founding chief compliance officer at four NYSE- and Nasdaq-listed companies.
• He has advised boards through SEC reporting cycles, contested transactions, government investigations, a U.S. Supreme Court decision, and two exits valued above $1.3 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BetterLife Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001477932-26-004714), on August 05, 2026, and is solely responsible for the information contained therein.